Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

Authors

Bernard Zinman
Christoph Wanner
John M. Lachin, George Washington UniversityFollow
David Fitchett
Erich Bluhmki
Stefan Hantel
Michaela Mattheus
Theresa Devins
Odd Erik Johansen
Hans J Woerle
Uli C Broedl
Silvio E Inzucchi

Document Type

Journal Article

Publication Date

9-17-2015

Journal

New england journal of medicine

Volume

373

Issue

22

Inclusive Pages

2117-2128

DOI

10.1056/NEJMoa1504720

Keywords

Benzhydryl Compounds--therapeutic use; Cardiovascular Diseases--prevention & control; Diabetes Mellitus, Type 2--drug therapy; Glucosides--therapeutic use; Hypoglycemic Agents--therapeutic use

APA Citation

Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Inzucchi, S.E. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes." New England Journal of Medicine, 373(22), 2117-2128. doi:10.1056/NEJMoa1504720

Peer Reviewed

1